Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Aneustat

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background:Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2018
2018
Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that… Expand
Is this relevant?
2017
2017
......................................................................................................................................... ii Lay Summary ............................................................................................................................... iv Preface .............................................................................................................................................v Table of 
  • figure 1.1
  • figure 2.1
  • figure 2.2
  • figure 2.3
  • figure 2.4
Is this relevant?
2014
2014
The current first‐line treatment for advanced metastatic prostate cancer, i.e. docetaxel‐based therapy, is only marginally… Expand
Is this relevant?
2007
2007
C67 Aneustat (OMN54), a natural product derivative, has anti-tumor, anti-inflammatory and immuno-modulatory activity as a single… Expand
Is this relevant?